Lindbrook Capital’s Axcelis ACLS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
$15.2K Buy
306
+240
+364% +$15.2K ﹤0.01% 1471
2024
Q4
$4.61K Buy
66
+32
+94% +$2.66K ﹤0.01% 2016
2024
Q3
$3.56K Buy
34
+15
+79% +$1.75K ﹤0.01% 2148
2024
Q2
$2.7K Buy
19
+14
+280% +$1.61K ﹤0.01% 2250
2024
Q1
$558 Hold
5
﹤0.01% 2506
2023
Q4
$648 Sell
5
-11
-69% -$1.52K ﹤0.01% 2546
2023
Q3
$2.61K Buy
16
+9
+129% +$1.58K ﹤0.01% 2028
2023
Q2
$1.28K Buy
7
+2
+40% +$288 ﹤0.01% 2315
2023
Q1
$666 Hold
5
﹤0.01% 2545
2022
Q4
$397 Sell
5
-10
-67% -$705 ﹤0.01% 2630
2022
Q3
$1K Buy
+15
New +$969 ﹤0.01% 2208

Other funds holding ACLS

Lindbrook Capital's ACLS Position: Q1 2025 in Review

Lindbrook Capital increased its Axcelis (ACLS) stake by 364% in Q1 2025, buying an estimated $15.2K and bringing the position to 306 shares worth $15.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1471.

Lindbrook Capital first reported a position in ACLS in Q3 2022 and has held it in 11 quarters since. 306 funds tracked by Wall St. Rank hold ACLS as of Q1 2025.

  • Lindbrook Capital held 306 shares of Axcelis worth $15.2K as of Q1 2025.
  • Lindbrook Capital bought 240 Axcelis shares in Q1 2025, an estimated $15.2K.
  • Axcelis made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1471 holding.
  • Lindbrook Capital first reported a position in Axcelis in Q3 2022 and has held it in 11 quarters since.
  • 306 funds tracked by Wall St. Rank held Axcelis as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.